Ryan Preblick - 14 Mar 2026 Form 4 Insider Report for Indivior Pharmaceuticals, Inc. (INDV)

Role: Chief Financial Officer
Signature: /s/Alice Givens, Power of Attorney
Issuer symbol: INDV
Transactions as of: 14 Mar 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Mar 2026, 16:32:18 UTC
Previous filing: 05 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Preblick Ryan	Chief Financial Officer	10710 MIDLOTHIAN TURNPIKE, SUITE 125, NORTH CHESTERFIELD	/s/Alice Givens, Power of Attorney	17 Mar 2026	0002014866

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	INDV	Common Stock	Options Exercise		+6,302	+2%		323,594	14 Mar 2026	Direct	F1
transaction	INDV	Common Stock	Tax liability		-2,843	-0.88%	$31.11^*	320,751	14 Mar 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	INDV	Restricted Stock Units	Options Exercise		-6,302	-100%		0	14 Mar 2026	Common Stock	6,302	$0.000000	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Restricted stock units (RSUs) convert into shares of the Issuer's common stock on a one-for-one basis.
F2	Shares used to satisfy tax withholding obligations associated with the vesting of RSUs on March 14, 2026.
F3	On March 14, 2024, the reporting person was granted 6,302 RSUs in accordance with the Indivior Group Deferred Bonus Plan 2018. Those RSUs vested in a single installment on March 14, 2026.